Pharmacogenetics of antidepressant response: an update

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Pharmacogenetics of antidepressant response : an update. / Drago, Antonio; De Ronchi, Diana; Serretti, Alessandro.

I: Human Genomics (Online), Bind 3, Nr. 3, 04.2009, s. 257-74.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Drago, A, De Ronchi, D & Serretti, A 2009, 'Pharmacogenetics of antidepressant response: an update', Human Genomics (Online), bind 3, nr. 3, s. 257-74. https://doi.org/10.1186/1479-7364-3-3-257

APA

Drago, A., De Ronchi, D., & Serretti, A. (2009). Pharmacogenetics of antidepressant response: an update. Human Genomics (Online), 3(3), 257-74. https://doi.org/10.1186/1479-7364-3-3-257

CBE

Drago A, De Ronchi D, Serretti A. 2009. Pharmacogenetics of antidepressant response: an update. Human Genomics (Online). 3(3):257-74. https://doi.org/10.1186/1479-7364-3-3-257

MLA

Drago, Antonio, Diana De Ronchi og Alessandro Serretti. "Pharmacogenetics of antidepressant response: an update". Human Genomics (Online). 2009, 3(3). 257-74. https://doi.org/10.1186/1479-7364-3-3-257

Vancouver

Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Human Genomics (Online). 2009 apr.;3(3):257-74. https://doi.org/10.1186/1479-7364-3-3-257

Author

Drago, Antonio ; De Ronchi, Diana ; Serretti, Alessandro. / Pharmacogenetics of antidepressant response : an update. I: Human Genomics (Online). 2009 ; Bind 3, Nr. 3. s. 257-74.

Bibtex

@article{27ee588348184a87957e415ab57e2bfb,
title = "Pharmacogenetics of antidepressant response: an update",
abstract = "The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.",
keywords = "Antidepressive Agents, Depression, Humans, Pharmacogenetics, United States",
author = "Antonio Drago and {De Ronchi}, Diana and Alessandro Serretti",
year = "2009",
month = apr,
doi = "10.1186/1479-7364-3-3-257",
language = "English",
volume = "3",
pages = "257--74",
journal = "Human Genomics (Online)",
issn = "1479-7364",
publisher = "BioMed Central Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Pharmacogenetics of antidepressant response

T2 - an update

AU - Drago, Antonio

AU - De Ronchi, Diana

AU - Serretti, Alessandro

PY - 2009/4

Y1 - 2009/4

N2 - The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.

AB - The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.

KW - Antidepressive Agents

KW - Depression

KW - Humans

KW - Pharmacogenetics

KW - United States

U2 - 10.1186/1479-7364-3-3-257

DO - 10.1186/1479-7364-3-3-257

M3 - Journal article

C2 - 19403460

VL - 3

SP - 257

EP - 274

JO - Human Genomics (Online)

JF - Human Genomics (Online)

SN - 1479-7364

IS - 3

ER -